Post-Operative Pain - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 187 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Post-Operative Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Post-Operative Pain - Pipeline Review, H2 2016', provides an overview of the Post-Operative Pain pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
- The report reviews pipeline therapeutics for Post-Operative Pain by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Post-Operative Pain therapeutics and enlists all their major and minor projects
- The report assesses Post-Operative Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Post-Operative Pain

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Post-Operative Pain Overview 8
Therapeutics Development 9
Pipeline Products for Post-Operative Pain - Overview 9
Post-Operative Pain - Therapeutics under Development by Companies 10
Post-Operative Pain - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Post-Operative Pain - Products under Development by Companies 17
Post-Operative Pain - Companies Involved in Therapeutics Development 20
AcelRx Pharmaceuticals, Inc. 20
Adynxx, Inc. 21
AngioChem Inc. 22
AskAt Inc. 23
Boehringer Ingelheim GmbH 24
Cara Therapeutics, Inc. 25
Colby Pharmaceutical Company 26
Cytogel Pharma, LLC 27
Dompe Farmaceutici S.p.A. 28
DURECT Corporation 29
Echo Pharmaceuticals B.V. 30
Fujimoto Pharmaceutical Corporation 31
Galleon Pharmaceuticals 32
Grunenthal GmbH 33
GW Pharmaceuticals Plc 34
Heron Therapeutics, Inc. 35
Immupharma Plc 36
Innocoll AG 37
INSYS Therapeutics, Inc. 38
Laboratorios Del Dr. Esteve S.A. 39
Lipocure Ltd. 40
Liquidia Technologies, Inc. 41
Medtronic plc 42
Orbis Biosciences, Inc. 43
Orion Oyj 44
Pacira Pharmaceuticals, Inc. 45
PainReform Ltd. 46
Pharmazz, Inc. 47
PhytoHealth Corporation 48
Proteus SA 49
Recro Pharma, Inc. 50
Relmada Therapeutics, Inc. 51
Serina Therapeutics, Inc. 52
SteadyMed Therapeutics, Inc. 53
Takeda Pharmaceutical Company Limited 54
The Medicines Company 55
Trevena, Inc. 56
Post-Operative Pain - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Target 59
Assessment by Mechanism of Action 62
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
(bupivacaine hydrochloride + meloxicam) - Drug Profile 69
AM-4 - Drug Profile 71
ANG-2002 - Drug Profile 72
ARX-04 - Drug Profile 73
AYX-1 - Drug Profile 78
BI-1026706 - Drug Profile 80
bupivacaine hydrochloride - Drug Profile 81
bupivacaine hydrochloride - Drug Profile 82
bupivacaine hydrochloride - Drug Profile 83
bupivacaine hydrochloride - Drug Profile 84
bupivacaine hydrochloride ER - Drug Profile 85
bupivacaine hydrochloride SR - Drug Profile 86
buprenorphine hydrochloride - Drug Profile 91
CPC-123 - Drug Profile 92
CR-4056 - Drug Profile 93
Cyt-1010 - Drug Profile 94
dexmedetomidine hydrochloride - Drug Profile 96
DF-2755A - Drug Profile 99
difelikefalin - Drug Profile 100
difluprednate XR - Drug Profile 107
dronabinol - Drug Profile 108
Drug for Post Operative Pain - Drug Profile 110
ECP-1014 - Drug Profile 111
fadolmidine hydrochloride - Drug Profile 112
fentanyl - Drug Profile 113
GAL-044 - Drug Profile 114
grapiprant - Drug Profile 115
IPP-102199 - Drug Profile 117
ketamine hydrochloride - Drug Profile 118
ketorolac tromethamine - Drug Profile 120
levorphanol tartrate ER - Drug Profile 121
MDT-10013 - Drug Profile 123
meloxicam - Drug Profile 124
meloxicam ER - Drug Profile 127
meloxicam ER - Drug Profile 128
MR-309 - Drug Profile 129
nabiximols - Drug Profile 131
nalbuphine hydrochloride - Drug Profile 138
neosaxitoxin - Drug Profile 139
oliceridine - Drug Profile 141
PMZ-2010 - Drug Profile 146
RBM-004 - Drug Profile 147
ropivacaine - Drug Profile 148
ropivacaine ER - Drug Profile 149
SER-226 - Drug Profile 150
Small Molecule for Post-Operative Pain - Drug Profile 151
sufentanil citrate - Drug Profile 152
tapentadol hydrochloride - Drug Profile 160
tramadol hydrochloride - Drug Profile 162
tramadol hydrochloride ER - Drug Profile 163
URB-937 - Drug Profile 164
VVZ-149 - Drug Profile 165
Post-Operative Pain - Dormant Projects 166
Post-Operative Pain - Discontinued Products 171
Post-Operative Pain - Product Development Milestones 172
Featured News & Press Releases 172
Appendix 182
Methodology 182
Coverage 182
Secondary Research 182
Primary Research 182
Expert Panel Validation 182
Contact Us 182
Disclaimer 183

List of Tables

Number of Products under Development for Post-Operative Pain, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Number of Products under Development by Companies, H2 2016 (Contd..1) 15
Number of Products under Development by Companies, H2 2016 (Contd..2) 16
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Development, H2 2016 19
Comparative Analysis by Unknown Stage Development, H2 2016 20
Products under Development by Companies, H2 2016 21
Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 (Contd..2) 23
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2016 24
Post-Operative Pain - Pipeline by Adynxx, Inc., H2 2016 25
Post-Operative Pain - Pipeline by AngioChem Inc., H2 2016 26
Post-Operative Pain - Pipeline by AskAt Inc., H2 2016 27
Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016 28
Post-Operative Pain - Pipeline by Cara Therapeutics, Inc., H2 2016 29
Post-Operative Pain - Pipeline by Colby Pharmaceutical Company, H2 2016 30
Post-Operative Pain - Pipeline by Cytogel Pharma, LLC, H2 2016 31
Post-Operative Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 32
Post-Operative Pain - Pipeline by DURECT Corporation, H2 2016 33
Post-Operative Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016 34
Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corporation, H2 2016 35
Post-Operative Pain - Pipeline by Galleon Pharmaceuticals, H2 2016 36
Post-Operative Pain - Pipeline by Grunenthal GmbH, H2 2016 37
Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016 38
Post-Operative Pain - Pipeline by Heron Therapeutics, Inc., H2 2016 39
Post-Operative Pain - Pipeline by Immupharma Plc, H2 2016 40
Post-Operative Pain - Pipeline by Innocoll AG, H2 2016 41
Post-Operative Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016 42
Post-Operative Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 43
Post-Operative Pain - Pipeline by Lipocure Ltd., H2 2016 44
Post-Operative Pain - Pipeline by Liquidia Technologies, Inc., H2 2016 45
Post-Operative Pain - Pipeline by Medtronic plc, H2 2016 46
Post-Operative Pain - Pipeline by Orbis Biosciences, Inc., H2 2016 47
Post-Operative Pain - Pipeline by Orion Oyj, H2 2016 48
Post-Operative Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016 49
Post-Operative Pain - Pipeline by PainReform Ltd., H2 2016 50
Post-Operative Pain - Pipeline by Pharmazz, Inc., H2 2016 51
Post-Operative Pain - Pipeline by PhytoHealth Corporation, H2 2016 52
Post-Operative Pain - Pipeline by Proteus SA, H2 2016 53
Post-Operative Pain - Pipeline by Recro Pharma, Inc., H2 2016 54
Post-Operative Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016 55
Post-Operative Pain - Pipeline by Serina Therapeutics, Inc., H2 2016 56
Post-Operative Pain - Pipeline by SteadyMed Therapeutics, Inc., H2 2016 57
Post-Operative Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 58
Post-Operative Pain - Pipeline by The Medicines Company, H2 2016 59
Post-Operative Pain - Pipeline by Trevena, Inc., H2 2016 60
Assessment by Monotherapy Products, H2 2016 61
Assessment by Combination Products, H2 2016 62
Number of Products by Stage and Target, H2 2016 64
Number of Products by Stage and Mechanism of Action, H2 2016 67
Number of Products by Stage and Route of Administration, H2 2016 70
Number of Products by Stage and Molecule Type, H2 2016 72
Post-Operative Pain - Dormant Projects, H2 2016 170
Post-Operative Pain - Dormant Projects (Contd..1), H2 2016 171
Post-Operative Pain - Dormant Projects (Contd..2), H2 2016 172
Post-Operative Pain - Dormant Projects (Contd..3), H2 2016 173
Post-Operative Pain - Dormant Projects (Contd..4), H2 2016 174
Post-Operative Pain - Discontinued Products, H2 2016 175